

JC.
NOV. 16. 2004 4:23PM

JCWSCS 17 NOV 2004

TOWNSEND & TOWNSEND

NO. 0187 P. 1

Atty Docket No. 015389-002980US

PTO FAX NO.: 703-746-9195
TELEPHONE NO.: 703-308-1202

OFFICIAL COMMUNICATION
FOR THE ATTENTION OF
Office of Initial Patent Examination
(OIPE)

CERTIFICATION OF FACSIMILE TRANSMISSION


I hereby certify that the following document(s) in re Application of Thomas R. Cech et al., Application No. 10/053,758, filed January 18, 2002, for ANTIBODY TO TELOMERASE REVERSE TRANSCRIPTASE (AMENDED) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Document(s) Attached

1. Transmittal Form (1 page)
2. Request for Corrected Filing Receipt (2 pages)
3. Copy of Corrected Filing Receipt (marked) (2 pages)
4. Supplemental Application Data Sheet (5 pages)

Number of pages being transmitted, including this page: 11

Dated: November 16, 2004


Janet L. Newmaker


PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (303) 571-4321


TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, CA 94111-3834
Telephone: 303-571-4000
Fax: 303-571-4321
60358402 v1

PTO/SB/21 (09-04)

TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/053,758	
	Filing Date	January 18, 2002	
	First Named Inventor	Thomas R. Cech	
	Art Unit	1642	
	Examiner Name	Not Known	
Total Number of Pages in This Submission	10	Attorney Docket Number	015389-002980US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Request For Corrected Filing Receipt Copy of Corrected Filing Receipt (marked) Supplemental Application Data Sheet
Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	Scott L. Ausenhus		
Date	November 16, 2004	Reg. No.	42,271

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Fax No. 703-748-9195, on November 16, 2004.			
Signature			
Typed or printed name	Janet L. Newmaker	Date	November 16, 2004

60358396 v1

NOV. 16. 2004 4:24PM

TOWNSEND & TOWNSEND

NO. 0187 P. 3

I hereby certify that this correspondence is being facsimile transmitted to the US Patent and Trademark Office, Fax No. 703-746-9195, on November 16, 2004.

PATENT
Attorney Docket No.: 015389-002980US
Client Ref. No.: 018/183C

TOWNSEND and TOWNSEND and CREW LLP

By: Janet L. Newmaker
Janet L. Newmaker

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Thomas R. Cech et al.

Application No.: 10/053,758

Filed: January 18, 2002

For: ANTIBODY TO TELOMERASE
REVERSE TRANSCRIPTASE
(AMENDED)

Customer No.: 34151

Confirmation No.: 6144

Examiner: Not Known

Art Unit: 1642

**REQUEST FOR CORRECTED FILING
RECEIPT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the Corrected Filing Receipt received from the US Patent and Trademark Office for the above-identified application for which issuance of another Corrected Filing Receipt is respectfully requested. The requested correction is indicated below and on the Filing Receipt. Also attached is a Supplemental Application Data Sheet which reflects this change.

The address of the fourth inventor has changed as follows.

Karen B. Chapman, Mill Valley, CA

Thomas R. Cech et al.
Application No.: 10/053,758
Page 2

PATENT

The Applicants believe no fee is required for submission of this Request. If a fee is required, however, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430.

Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

Date: November 16, 2004

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 303-571-4321
SLA/jln
60358391 v1



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1490
 Alexandria, Virginia 22313-4490
 www.uspto.gov

APPL NO.	FILING OR 371 (e) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/053,758	01/18/2002	1642	860	015389-002980US	78	22	4

CONFIRMATION NO. 6144

CORRECTED FILING RECEIPT



OC000000013652188

34151
 TOWNSEND AND TOWNSEND AND CREW LLP
 8TH FLOOR
 TWO EMBARCADERO CENTER
 SAN FRANCISCO, CA 94111

Date Mailed: 08/30/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Thomas R. Cech, Potomac, MD;
 Joachim Lingner, Epalinges, SWITZERLAND;
 Toru Nakamura, San Diego, CA;
 Karen B. Chapman, ~~Southborough, MA~~; *mill Valley, CA*
 Gregg B. Morin, Oakville, CANADA;
 Calvin B. Harley, Palo Alto, CA;
 William H. Andrews, Reno, NV;

Domestic Priority data as claimed by applicant

This application is a CON of 09/843,676 04/26/2001
 which is a CON of 08/854,050 05/09/1997 PAT 6,261,836
 which is a CIP of 08/851,843 05/06/1997 PAT 6,093,809
 which is a CIP of 08/846,017 04/25/1997 ABN
 which is a CIP of 08/844,419 04/18/1997 ABN

Foreign Applications

If Required, Foreign Filing License Granted: 02/15/2002

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Title

Antibody to telomerase reverse transcriptase

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).